JUL 24, 2024 | 3:58 PM PDT | BIOCENTURY | MANAGEMENT TRACKS TRIMARCHI BECOMES PRESIDENT, COO OF BRIDGEBIO BY Plus: New CEO, CFO at Beacon and updates from enGene, Broken String and Nashvillehttps://www.biocentury.com/article/653058/trimarchi-becomes-president-coo-of-bridgebio© 2024 BioCentury Inc. All Rights Reserved ..read more

JUL 24, 2024 | 3:08 PM PDT | BIOCENTURY | PRODUCT DEVELOPMENT BENCHMARKING LEAD-212: SSTR2 TEST KITCHEN BY The clinical data available for lead-212 provides initial proof-of-concept for its efficacy and safety in radioligand therapies for cancerhttps://www.biocentury.com/article/653026/benchmarking-lead-212-sstr2-test-kitchen© 2024 BioCentury Inc. All Rights Reserved ..read more

JUL 24, 2024 | 12:05 PM PDT | BIOCENTURY | POLITICS, POLICY & LAW PEDIATRIC PRIORITY REVIEW VOUCHER PROGRAM ON THE BRINK BY Law authorizing rare pediatric PRV sunsets Sept. 30 and despite bipartisan support Congress is ditheringhttps://www.biocentury.com/article/653054/pediatric-priority-review-voucher-program-on-the-brink© 2024 BioCentury Inc. All Rights Reserved ..read more

JUL 23, 2024 | 4:15 PM PDT | BIOCENTURY | MANAGEMENT TRACKS ARMSTRONG RETURNS TO DANA-FARBER BY Plus: The Carlyle Group’s Rubenstein to join Moderna’s board and updates from Geron, Vedanta, Vericel, Metrion and PharmaEssentiahttps://www.biocentury.com/article/653043/armstrong-returns-to-dana-farber© 2024 BioCentury Inc. All Rights Reserved ..read more

JUL 23, 2024 | 4:05 PM PDT | BIOCENTURY | DATA BYTE ACCELERATED APPROVALS OF EPKINLY, AUGTYRO, KRAZATI AMONG FDA’S JUNE LABEL EXPANSIONS BY The month also brought conversions to full approval for Retevmo and Sirturohttps://www.biocentury.com/article/653019/accelerated-approvals-of-epkinly-augtyro-krazati-among-fda-s-june-label-expansions© 2024 BioCentury Inc. All Rights Reserved ..read more

JUL 23, 2024 | 3:14 PM PDT | BIOCENTURY | PRODUCT DEVELOPMENT CLINICAL REPORT: IONIS’ THERAPY FOR ANGELMAN SYNDROME HEADING FOR PHASE III BY Plus: Data from Innovent, Agenus, Merck, Bayer and Orionhttps://www.biocentury.com/article/653041/clinical-report-ionis-therapy-for-angelman-syndrome-heading-for-phase-iii© 2024 BioCentury Inc. All Rights Reserved ..read more

JUL 23, 2024 | 2:49 PM PDT | BIOCENTURY | PRODUCT DEVELOPMENT LEAD-212’S LEADING PLAYERS BY Decisions about manufacturing and distribution could be make-or-break for drug developers producing their own lead-212 https://www.biocentury.com/article/653000/lead-212-s-leading-players© 2024 BioCentury Inc. All Rights Reserved ..read more

JUL 22, 2024 | 4:56 PM PDT | BIOCENTURY | MANAGEMENT TRACKS NIMA FARZAN NAMED CEO OF LATIGO BY Plus: Wu Changxiong succeeds Zhou Hua as CFO of Walvax, and updates from Hookipa, Janux, Akeso and Serinahttps://www.biocentury.com/article/653030/nima-farzan-named-ceo-of-latigo© 2024 BioCentury Inc. All Rights Reserved ..read more

JUL 22, 2024 | 4:39 PM PDT | BIOCENTURY | DEALS DEALS REPORT: SIONNA LOOKS TO ABBVIE FOR CYSTIC FIBROSIS COMBOS AS VERTEX-ORUM STRIKE DEGRADER DEAL BY Week's deals also include a radionuclide conjugate partnership between SK and Full-Life, and GT Apeiron hands off CDK7 to Exscientia https://www.biocentury.com/article/653024/deals-report-sionna-looks-to-abbvie-for-cystic-fibrosis-combos-as-vertex-orum-strike-degrader-deal© 2024 BioCentury Inc. All Rights Reserved ..read more

JUL 22, 2024 | 4:21 PM PDT | BIOCENTURY | PRODUCT DEVELOPMENT RADIOPHARMA Ɑ-EMITTERS, AZ’S GALBRAITH AND LNPS — A BIOCENTURY PODCAST BY Plus the latest data from Roche in the oral obesity racehttps://www.biocentury.com/article/653008/radiopharma-emitters-az-s-galbraith-and-lnps-a-biocentury-podcast© 2024 BioCentury Inc. All Rights Reserved ..read more